Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE-TMZ
2020-005437-32Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and irinotecan in colorectal cancer (CRC) and colon adenocarcinoma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started May 2021; status: active.
02
Drugs
temozolomideirinotecan
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on 2020-005437-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005437-32.